Feraheme has been approved to treat iron deficiency in adult chronic kidney disease patients, but the U.S. Food and Drug Administration has refused to clear the drug for use among patients suffering from adult iron deficiency anemia (IDA). …
The stock has gained more than 15% thus far this year ... Antares Pharma Inc. (ATRS) jumped 8.8% while Amag Pharmaceuticals Inc. (AMAG) climbed 17% after Amag said the U.S. Food and Drug Administration has approved …
The technology company had a solid second quarter and said it will buy back $25 billion in stock. Teva Pharmaceutical Industries ... struggled and forecast a smaller-than-expected profit. AMAG Pharmaceuticals Inc., up $4.05 to $17.95 …
The stock closed down 4.6% at $3.31 on Thursday but was indicated ... Thursday's top analyst calls included AMAG
Inc. AMAG. Shares have lost about 6.6% in the past month, underperforming the market. Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors …
AMAG closed Monday's trading at $13.25 ... BGNE closed Monday's trading at $130.62, down 4.58%. In after-hours, the stock was up 2.67% to $134.10. Calithera Biosciences Inc.'s (CALA) phase I study of CB-839 in combination with …
The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration of up to $350 million based on the …